What’s the optimal tumor model for your next preclinical immuno-oncology study?
Scientists at Covance have run close to 1,000 preclinical immuno-oncology studies over the past five years. While new models continue to be developed, our scientists have learned which five models are the commonly used “workhorse” models, time-tested and optimized for evaluating a wide range of therapeutic approaches.
The models discussed offer:
- Diverse histotypes for test agent development
- Data representing responsiveness to checkpoint inhibitors, costimulatory molecules, and/or focal radiation
- Corresponding links to posters and other data sources to aid in your decision-making process